UroGen Settles JELMYTO Patent Suit, Securing Exclusivity Until 2030
URGN has more than doubled off its 52-week low of $3.605.
Summary
UroGen Pharma has resolved patent litigation with Teva Pharmaceuticals concerning its key drug, JELMYTO. The settlement grants Teva a license to launch a generic version of JELMYTO starting September 15, 2030. This agreement effectively preserves nearly all of JELMYTO's patent protection, which extends to January 2031, removing a significant competitive threat and providing long-term revenue clarity for a core product. This positive development follows recent strong clinical data for other pipeline assets.
At the time of this announcement, URGN was trading at $26.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $3.61 to $32.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.